Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has received allowance of its patent applications in Europe and China covering diagnostic use of PV-10 and a number of related agents in computed tomography and magnetic resonance imaging or MRI.
Subscribe to our email newsletter
The pending patents cover products for diagnosis of cancer and other serious diseases.
Craig Dees, CEO of Provectus, said: “These cases augment our international portfolio of twenty-six issued patents and four pending patents, along with our US patent portfolio of sixteen issued and five pending patents. As important milestones, they demonstrate the scope of our patent activity that spans markets ranging from the developed world to the rapidly developing world.”